- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03814564
ASSESSment of Perfusion, Oxygen Saturation, Endothelial Function and Coagulation in Circulatory SHOCK (ASSESS-SHOCK)
ASSESSment of Peripheral Perfusion, Tissue Oxygen Saturation, Endothelial Function and Coagulation Disorder in Circulatory SHOCK, the ASSESS - SHOCK Study
Study Overview
Detailed Description
Background:
Circulatory shock is a frequent condition in the intensive care unit, comprising roughly one of three patients in the intensive care unit (ICU), and associated with high mortality rates. Current treatment guidelines state that one of the main goals for therapeutic interventions is to improve tissue perfusion to prevent subsequent organ dysfunction and death. In acute critical illness, up to one fourth of the patients develop severe hemostatic aberrations and coagulopathy, called disseminated intravascular coagulation (DIC), which is associated with excess mortality.
Despite differences in the underlying cause, acutely critically ill patients share similar features that may be driven by shock. This response, potentially escalating to life-threatening conditions, is relatively homogenous. The shock induced sympatho-adrenal hyperactivation may be a critical driver this endotheliopathy. If allowed to proceed uncontrollably, damages to the microcirculation and organ dysfunction may follow.
Near-infrared spectroscopy (NIRS), a non-invasive method based on the principles of light transmission and absorption, offers a non-invasive and continuous bedside method to assess tissue haemoglobin oxygen saturation (StO2), which may serve as an indirect measure of the adequacy of tissue perfusion. NIRS could potentially be used for early identification of patients with tissue hypoperfusion and therefore high risk of developing organ dysfunction, and may also be used for assessing frontal cerebral oxygen saturation in circulatory failure and its use is well documented in general anaesthesia in many patient groups. There are some data showing an association between low frontal StO2 values and delirium in the ICU. The use of near-infrared spectroscopy to measure tissue oxygenation in healthy humans has been well validated. However, assessing tissue oxygenation using NIRS in critically ill patients is less well established. The hemodynamic and other systemic responses in burns are similar to those in septic shock. However, the mechanisms behind these responses have not been compared between burn and septic shock patients to our knowledge. Overall, the knowledge of microcirculation and how to monitor it in burn patients is limited.
Objectives:
The objective of the observational cohort study is (1) to deduce whether measurements of peripheral NIRS (lower limb registered proximal of the knee cap) associate with the development of organ dysfunction as assessed by daily sequential organ failure assessment score (SOFA) in the ICU during days 1 to 7 in the ICU, (2) whether cerebral (frontal) StO2 values are associated with delirium in the ICU and (3) the association of frontal and peripheral StO2 with other micro- and macrohemodynamic parameters in this patient group , (4) to deduce the associations between shock, endotheliopathy, DIC and tissue perfusion and, last, the feasibility of central and peripheral NIRS monitoring in shock patients in the ICU using the INVOS tm NIRS StO2 appliances. In addition, the investigators target to evaluate (5) the incidence, evolution, and outcome of sepsis-associated disseminated intravascular coagulation (DIC), and (6) the associations between a) continuous hemodynamic data, b) laboratory data (such as syndecan-1 (SDC-1), vascular adhesion protein 1 (VAP1), CD73, heparin binding protein (HBP), endostatin, chromogranin, mitochondrial function tests, blood count d-dimer, INR, neuron specific enolase and metabolomics data) (7) and study associations of singlenucleotide polymorphisms with developing organ dysfunction and 90-day mortality. To compare the hemodynamic alterations of burn patients to septic patients with the intention to find new ways to monitor and manage hemodynamic and particularly microcirculation in burn patients.
Design:
Observational multi-center study
Patient population:
Patients with circulatory shock admitted to the intensive care units (ICU) fulfilling the inclusion criteria.
Sample size:
A minimum of 250patients with circulatory shock with NIRS registration A minimum of 400 patients with sepsis for evaluation of incidence of DIC and metabolomics and genetic tests (genome-wide association study, GWAS)
Methods:
Patients with circulatory shock admitted to the intensive care unit (ICU) fulfilling the inclusion criteria but none of the exclusion criteria within 4 hours of vasopressor inititation in the ICU and signs of clinical hypoperfusion or elevated lactate levels. Frontal and peripheral NIRS StO2 registration is performed using the Medtronic INVOS appliances and bilateral central and peripheral sensors for 48 hours from study inclusion. The INVOS NIRS registration is blinded and cannot be used for clinical decision making. The frontal and peripheral StO2 registrations will be collected for further analyses. Blood samples will be taken from an arterial cannula at inclusion, and at 12 h, 24h and 48h, blood gas samples will be drawn every 2 hours. Data on demographic data, health status, chronic illnesses and medications prior to ICU admission will be collected during the study. Hemodynamic data, information on vasopressor and inotrope medication, need and use of sedatives, fluid balance and specific ICU interventions during the ICU stay will also be collected, as well as daily intensive care delirium screening checklist (ICDSC) and SOFA-score registrations. An electronic case report form (CRF) will be used in the study. In addition to clinical data, data of feasibility and reported problems considering the use of NIRS StO2 registrations will be collected. Blood samples will be frozen and stored locally for further processing and analyses.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Helsinki, Finland, 00029
- Helsinki University Hospital
-
Kuopio, Finland, 70029 KYS
- Kuopio University Hospital
-
Tampere, Finland, 33521 Tampere
- Tampere University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Age ≥ 18 Critically ill patients requiring Intensive Care Unit (ICU) care with circulatory shock within 4 hours (≤ hours) of ICU admission or with circulatory shock developing in the ICU within 24 hours from ICU admission and within 4 hours of initiation of vasopressor treatment presenting with the below listed signs of for circulatory shock
Hypotension - need for vasopressor to achieve mean arterial pressure (MAP) ≥65 mmHg after 1L of crystalloid solution
and
Any sign of hypoperfusion (at least one of the signs below)
- blood lactate ≥2 mmol/L
- mottling score ≥ 2
- Base Excess (BE) ≤ - 5 mEq/L
- prolonged capillary refill time ≥ 2 s
- cool periphery beyond elbows or knees bilaterally
- altered mentation
OR
Confirmed or suspected infection and anti-microbial treatment
OR as an independent criteria for the ASSESS-SHOCK BURNS substudy
- Burn injury ≥30% total body surface area(TBSA), ICU admission within 12h of the injury, with or without hypotension and signs of hypoperfusion within 4 hours of ICU admission
Exclusion Criteria:
- Age < 18 years
- Pregnant or lactating
- Known refusal to any clinical study or this specific study
- Consent not obtained (according to local regulatory statements for ethical conduct of research)
- Out-of-hospital cardiac arrest (OHCA) patients
- Terminal illness and not considered for full intensive care support
- Planned postoperative admission
- Postoperative intensive care after organ transplantation
- Patients who are likely to be transferred to the ward in 24 hours
- Defects of skin, underlying tissues or extremities preventing the use of the central or peripheral NIRS probes (the first 250 enrolled patients)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Circulatory failure / NIRS monitoring
Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit (ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the (near-infrared spectroscopy) NIRS-substudy.
|
Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation.
Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy.
All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
|
Circulatory Failure / no NIRS monitoring
Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit(ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the near-infrared spectroscopy (NIRS) substudy.
All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring).
Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.
|
|
Gut dysbiosis, delirium and long term cognition
ASSESS-shock participants that have been treated at Meilahti ICU:s and survived the ICU admission to discharge, who are living in the Helsinki and Uusimaa Hospital District area or reasonable traveling distance to the unit for cognitive testing. Cognitive function testing is performed after ICU discharge and at 3 and 6 months after ICU discharge. Testing of the microbiome is performed by collecting and analyzing fecal samples at ICU admission and at 7 days after ICU admission. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in severity of Organ dysfunction during the first week in ICU (study period)
Time Frame: At 7 days in ICU
|
Change in the total Sequential Organ Failure Assessment (SOFA) score from day 1 to day 7 in the ICU, higher SOFA score indicates greater severity of organ failure, the total SOFA score ranges from 0-24 points
|
At 7 days in ICU
|
Average severity of Organ dysfunction during the first 7 days in the ICU (study period)
Time Frame: First week in the Intensive Care Unit after admission
|
Average Sequential Organ Failure Assessment (SOFA) during days 1 to day 7 in the ICU, higher SOFA score indicates greater severity of organ failure, the total SOFA score ranges from 0-24 points
|
First week in the Intensive Care Unit after admission
|
New organ dysfunctions
Time Frame: First week in the Intensive Care Unit after admission
|
Number of new organ dysfunctions (new organ dysfunction defined as one of 6 SOFA subscores ≥3 points/ total 4 points, higher points indicate greater severity.
Only one new organ dysfunction / each subscore can be used for calculation of total number of new organ dysfunctions in one week
|
First week in the Intensive Care Unit after admission
|
90-day mortality
Time Frame: 90 days
|
Death within 90 days from ICU admission
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
28-day mortality
Time Frame: 28 days
|
28-day mortality
|
28 days
|
ICU length of stay
Time Frame: 90 days
|
ICU length of stay
|
90 days
|
Intensive care delirium incidence
Time Frame: First week in the Intensive Care Unit after admission
|
Delirium diagnosis in the ICU assessed by Intensive Care Delirium Scoring Checklist (ICDSC) scoring during days 1-7 defined as ICDSC score value of four points or more ( total score: 0-8 points)
|
First week in the Intensive Care Unit after admission
|
Intensive care delirium severity
Time Frame: First week in the Intensive Care Unit after admission
|
Number of Intensive Care Delirium Scoring Checklist (ICDSC) scores (assessment performed twice daily) of ≥4 points indicating presence of delirium during days 1-7
|
First week in the Intensive Care Unit after admission
|
Intensive care delirium scoring checklist aggregate and average score during first week in intensive care
Time Frame: First week in the Intensive Care Unit after admission
|
Aggregate Intensive Care Delirium Scoring Checklist (ICDSC) scores during days 1-7 .
Total score ranges from 0 to 8 points.
The aggregate score of all daily ICDSC measurements ( sum of all daily scores performed twice daily) will be divided by number of measurements to adjust for possible differences in number of measurements (= average ICDSC score)
|
First week in the Intensive Care Unit after admission
|
INVOS NIRS feasibility and safety questionnaire
Time Frame: 0-48 hours in Intensive Care Unit after enrolment into study
|
Feasibility of frontal and peripheral near-infrared spectroscopy tissue (NIRS) haemoglobin oxygen saturation (StO2) assessment in circulatory shock during the 48 h registration.
Feasibility and registration issues are assessed using a questionnaire.
Feasibility will be assessed every eight hours ( during each nurse's shift assessing feasibility and saefty on a scale from 0 to 5. Higher score indicatesmore severe feasibility issues
|
0-48 hours in Intensive Care Unit after enrolment into study
|
Time to Extubation
Time Frame: 28 days
|
Time to extubation
|
28 days
|
Days off ventilator in 28 days
Time Frame: 28 days
|
Days off ventilator in 28 days
|
28 days
|
Days without vasoactive medication in 28 days
Time Frame: 28 days
|
Days without vasopressor or inotropic medication
|
28 days
|
Days without RRT in 28 days
Time Frame: 28 days
|
Days without renal replacement therapy of any kind in 28 days
|
28 days
|
Cognitive dysfunction after ICU discharge
Time Frame: 6 months
|
Cognitive dysfunction assessed by a set of neuropsychological tests
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycocalyx and endothelial injury biomarkers such as: Syndecan-1 (SDC-1), vascular adhesion protein 1 (VAP1), CD73, heparin binding protein (HBP), angiopoietin-2, endostatin, chromogranin
Time Frame: First week in the Intensive Care Unit after admission
|
Injury of the endothelium and glycocalyx
|
First week in the Intensive Care Unit after admission
|
Collaborators and Investigators
Investigators
- Principal Investigator: Erika Wilkman, MD, PhD, Helsinki University Central Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUS/420/2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Circulatory Failure
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAcute Circulatory Failure
-
Hospices Civils de LyonCompleted
-
Centre Hospitalier ArrasCompletedAcute Circulatory FailureFrance
-
Hospices Civils de LyonCompleted
-
University Hospital, BordeauxCompletedCirculatory Failure (Shock)France
-
University Hospital, AngersRecruitingShock | Hemodynamic Monitoring | Acute Circulatory FailureFrance
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingExtracorporeal Membrane Oxygenation Complication | Cerebral Circulatory FailureNetherlands
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Association pour le Développement et l'Organisation...CompletedAcute Circulatory Failure
-
Nantes University HospitalUnknownAcute Circulatory FailureFrance
Clinical Trials on NIRS monitoring
-
Stanford UniversityMedtronic - MITGCompletedIntraventricular Hemorrhage of Prematurity | Complications of PrematurityUnited States
-
Children's Hospital of PhiladelphiaMasimo CorporationRecruitingCongenital Disorders | Cerebral Desaturation | Neonatal SurgeryUnited States, United Kingdom, China, Australia, France, India, Brazil
-
AHEPA University HospitalMedtronic - MITGCompletedHeart DiseasesGreece
-
Vilnius UniversityUnknownWound Heal | Percutaneous Transluminal Angioplasty | Ischemic FeetLithuania
-
Medical University of ViennaTerminatedNontraumatic Compartment Syndrome of LegAustria
-
University of ManitobaCompletedRespiratory Distress SyndromeCanada
-
University of Wisconsin, MadisonMeriter FoundationRecruiting
-
IWK Health CentreRecruitingPreterm InfantCanada
-
KU LeuvenCAS Medical Systems, Inc.CompletedPediatric Congenital Heart SurgeryBelgium
-
University of PortsmouthPortsmouth Hospitals NHS TrustNot yet recruitingCompartment Syndrome Nontraumatic Lower ExtremityUnited Kingdom